One of the biggest topics in tech this year was the ever-expanding bubble in startup valuations, fueled by an ever-expanding pool of increasingly less qualified investors. We brought together our business editor Ben Popper, and our science editor, Liz Lopatto, to discuss what happens when you mix a flood of dumb money eager to invest in anything "disruptive" with life science companies that can actually impact our bodies and health. Here's what we learned in 2015.
Read Full Article »
